ArticleBMJ open respiratory research2020
Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation.
Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- Outcomes with venoarterial vs venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation in interstitial lung disease.JHLT open · 2025Article
- Early detection of pulmonary vasculopathy in children with sickle cell disease by new echocardiography-based blood speckle technology.BMC pediatrics · 2025Article
- Exercise-induced Right-to-left Shunt in a Patient with Combined Pulmonary Fibrosis and Emphysema.Internal medicine (Tokyo, Japan) · 2025Article
- Preacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study.American journal of respiratory and critical care medicine · 2024Article
- Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension.ERJ open research · 2024Article
- Imaging the Intersection of Parenchymal Abnormalities and Pulmonary Vascular Pathways.American journal of respiratory and critical care medicine · 2024Article
- Dissecting the lung transcriptome of pulmonary fibrosis-associated pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.Life (Basel, Switzerland) · 2024Review
- Effectiveness of upfront triple oral combination therapy with additional pirfenidone in a patient with severe pulmonary hypertension associated with lung diseases.Respirology case reports · 2024Article
- Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients.Medicina (Kaunas, Lithuania) · 2023Review
- Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension-A Challenging Mystery.Diagnostics (Basel, Switzerland) · 2023Review
- The vascular perspective on acute and chronic lung disease.The Journal of clinical investigation · 2023Review
- Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats.International journal of molecular sciences · 2023Article
- Review
- Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future.Frontiers in medicine · 2023Review
- Recent advances in the management of pulmonary hypertension with interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Beyond Bronchiolitis Obliterans: In-Depth Histopathologic Characterization of Bronchiolitis Obliterans Syndrome after Lung Transplantation.Journal of clinical medicine · 2021Article
- Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management.International journal of chronic obstructive pulmonary diseaseReview
- Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) causes increased morbidity and mortality in patients with interstitial lung diseases (ILD). Classification schemes, while well-characterised for the vasculopathy of idiopathic PH, have been applied, unchallenged, to ILD-related PH. We evaluated pulmonary arterial histopathology in explanted human lung tissue from patients who were transplanted for advanced fibrotic ILD.
methodsLung explants from 38 adult patients who underwent lung transplantation were included. Patients were divided into three groups: none, mild/moderate and severe PH by mean pulmonary artery pressure (mPAP) measured at pre lung transplantation right heart catheterisation (RHC). Grading of pulmonary vasculopathy according to Heath and Edwards scheme, and prelung transplantation evaluation data were compared between the groups.
results38 patients with fibrotic ILDs were included, the majority (21) with idiopathic pulmonary fibrosis. Of the 38 patients, 18 had severe PH, 13 had mild/moderate PH and 7 had no PH by RHC. 16 of 38 patients had severe pulmonary arterial vasculopathy including vascular occlusion with intimal fibrosis and/or plexiform lesions. There were no correlations between mPAP and lung diffusion with the severity of pulmonary arterial pathological grade (Spearman's rho=0.14, p=0.34, rho=0.11, p=0.49, respectively).
conclusionsPatients with end stage ILD had severe pulmonary arterial vasculopathy in their explanted lungs irrespective of the presence and/or severity of PH as measured by RHC. These findings suggest that advanced pulmonary arterial vasculopathy is common in patients with advanced fibrotic ILD and may develop prior to the clinical detection of PH by RHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.